Front Med (Lausanne). 2025 Mar 21;12:1541461. doi: 10.3389/fmed.2025.1541461. eCollection 2025.
3
The efficacy, safety, and persistence of vedolizumab versus adalimumab in patients with inflammatory bowel disease: a systematic review and meta-analysis.
维多珠单抗与阿达木单抗治疗炎症性肠病患者的疗效、安全性及持久性:一项系统评价和荟萃分析。
Inflammopharmacology. 2025 Apr;33(4):1761-1773. doi: 10.1007/s10787-025-01710-4. Epub 2025 Mar 15.